Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis | MicrobiomeTrials← Back to trialsNCT05938361
Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis
CompletedOBSERVATIONAL
Trial Details
Start: 2023-06-01Est. Completion: 2024-11-01
Enrollment target: 160 participants Locations- Service de Dermatologie- Hopital Saint Joseph, Paris, France
Other microbiome trials you might be interested in
Palmoplantar Pustulosis (PPP)
Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and sc…
Shenyang, ChinaEst. completion Dec 2027
PsoriasisCardiovascular DiseasesCardiovascular Risk FactorCardiovascular PathologyPsoriasis VulgarisPsoriatic NailPsoriasis FacePsoriasis GuttatePsoriasis Gyrata
Psoriasis Diffusa
Psoriasis Palmaris
Psoriasis Annularis
Psoriasis Circinata
Psoriasis Plantaris
Psoriasis Universalis
Psoriasis Geographica
Left Ventricular Dysfunction
Myocardial Infarction
Myocardial Ischemia
Heart Failure
Stroke
Heart Diseases
Heart Failure, Systolic
Heart Failure, Diastolic
In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarke…
Hellerup, DenmarkEst. completion Oct 1, 2034